Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/136230
Full metadata record
DC FieldValueLanguage
dc.creatorDueñas, M
dc.creatorPérez-Figueroa, A
dc.creatorOliveira, C
dc.creatorSuárez-Cabrera, C
dc.creatorSousa, A
dc.creatorOliveira, P
dc.creatorVillacampa, F
dc.creatorParamio, JM
dc.creatorMartínez-Fernández, M
dc.date.accessioned2021-09-20T10:52:10Z-
dc.date.available2021-09-20T10:52:10Z-
dc.date.issued2019
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/10216/136230-
dc.description.abstractNon-muscle invasive bladder cancer (NMIBC) represents a crucial problem for the national health care systems due to its high rates of recurrence and the consequent need of frequent follow-ups. Here, gene expression analyses in patients diagnosed as NMIBC were performed to determine those molecular pathways involved in tumor initiation, finding that both MYC and E2F are up regulated and helps to tumor initiation and progression. Our results also support an important involvement of alternative splicing events, modifying key pathways to favour bladder tumor evolution. Finally, since MDM2 showed differential exon usage, mutations in TP53 and its protein expression have been also studied in the same patients. Our data support that recurrence is epigenetically mediated and favoured by an increase protein expression of TP53, which appears more frequently mutated in advanced stages and grades, being associated to a worse prognosis. Therefore, TP53 mutational status could be used as a potential biomarker in the first stages of NMIBC to predict recurrence and prognosis.
dc.description.sponsorshipWe express our deepest acknowledgement to patients and their families. The authors also acknowledge the computing resources and technical support provided by Abel Paz-Gallardo and Alfonso Pardo from Extremadura Research Centre for Advanced Technologies (CETA−CIEMAT). This work was supported FEDER cofounded MINECO grant SAF2015-66015-R, ISCIII-RETIC RD12/0036/0009, and PIE15/00076 and CB/16/00228 (to J.M. Paramio); MMF was supported by a Jose Castillejo Fellowship (CAS16/00115).
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.ispartofScientific Reports, vol.9(1):10362
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.meshAlternative Splicing
dc.subject.meshCarcinoma, Transitional Cell / genetics
dc.subject.meshCarcinoma, Transitional Cell / pathology
dc.subject.meshDisease-Free Survival
dc.subject.meshE2F Transcription Factors / genetics
dc.subject.meshExons / genetics
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshGene Ontology
dc.subject.meshGenes, myc
dc.subject.meshGenes, p53
dc.subject.meshHumans
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshMutation, Missense
dc.subject.meshNeoplasm Invasiveness
dc.subject.meshNeoplasm Proteins / biosynthesis
dc.subject.meshNeoplasm Proteins / genetics
dc.subject.meshPapilloma / genetics
dc.subject.meshPapilloma / pathology
dc.subject.meshPrognosis
dc.subject.meshProto-Oncogene Proteins c-mdm2 / genetics
dc.subject.meshProto-Oncogene Proteins c-myc / genetics
dc.subject.meshRecurrence
dc.subject.meshTissue Array Analysis
dc.subject.meshUrinary Bladder Neoplasms / genetics
dc.subject.meshUrinary Bladder Neoplasms / pathology
dc.subject.meshWhole Exome Sequencing
dc.titleGene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.1038/s41598-019-46652-4
dc.relation.publisherversionhttps://www.nature.com/articles/s41598-019-46652-4
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.1038-s41598-019-46652-4.pdf2.57 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons